Medication review in Parkinson

A Study Assessing The Effect Of A Structured Medication Review On Quality Of Life In Patients With Parkinson’s Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21486

Enrollment

198

Registered

2014-03-17

Start date

2014-05-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease Therapy adherence Medication Polypharmacy

Interventions

The study is a prospective randomized, controlled trial (RCT). As intervention, community pharmacists perform a structured medication review as one-time assessment at the start of the study within t

Eligibility

Inclusion criteria

Inclusion criteria: The patient has/is: • Diagnosed with PD according to the UK-brain banking criteria • ≥ Eighteen years of age • ≥ Four different medications daily • ≥ Four medication intake moments daily • Expressing motor symptoms or non-motor symptoms • Living (semi)-independent in the region of Enschede • Able to read and write the Dutch language

Exclusion criteria

Exclusion criteria: The patient has/is: • Unable to administrate own medications, excluding PD patients with personal or family home caregivers • Received a medication review within a year before the study

Design outcomes

Primary

Measure	Time frame
The primary objective of the study is to assess whether a structured medication review improves medication adherence and leads to better quality of life in patients with PD after a follow-up of three months and six months, compared to patients with PD who will not receive a structured medication review during follow-up. Disease-specific quality of life will be measured, using the Parkinson’s Disease Questionnaire-39 (PDQ-39).	—

Measure

Time frame

The primary objective of the study is to assess whether a structured medication review improves medication adherence and leads to better quality of life in patients with PD after a follow-up of three months and six months, compared to patients with PD who will not receive a structured medication review during follow-up. Disease-specific quality of life will be measured, using the Parkinson’s Disease Questionnaire-39 (PDQ-39).

—

Secondary

Measure	Time frame
The secondary objectives of the study are measurements of activities in daily life and physical disability, mobility and motor symptoms, non-motor symptoms, cost-effectiveness and health state, and personal carers’ quality of life, by comparing the results of PD patients who receive a medication review with PD patients who will not receive a medication review. The effects will be measured by using the AMC Linear Disability Scale (ALDS), the Non Motor Symptoms Questionnaire (NMSQuest), the EuroQOL-5 Dimensions (EQ-5D), the Visual Analogue Scale (VAS), and the PDQ carer questionnaire.	—

Measure

Time frame

The secondary objectives of the study are measurements of activities in daily life and physical disability, mobility and motor symptoms, non-motor symptoms, cost-effectiveness and health state, and personal carers’ quality of life, by comparing the results of PD patients who receive a medication review with PD patients who will not receive a medication review. The effects will be measured by using the AMC Linear Disability Scale (ALDS), the Non Motor Symptoms Questionnaire (NMSQuest), the EuroQOL-5 Dimensions (EQ-5D), the Visual Analogue Scale (VAS), and the PDQ carer questionnaire.

—

Contacts

Public ContactJ. Palen, van der

Medisch Spectrum Twente, P.O. Box 50000

+31 (0)53 4872023

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)